- The disease
- Retinitis pigmentosa type 11 (RP11) is a rare, inherited form of retinal degeneration caused by mutations in the PRPF31 gene, which encodes a protein involved in RNA splicing in the photoreceptor cells of the eye. The condition leads to progressive loss of peripheral and, eventually, central vision. It follows an autosomal dominant inheritance pattern, meaning a single mutated copy of the gene is sufficient to cause disease. There are currently no approved disease-modifying treatments for RP11.
- What the asset is trying to do
- VP-001 is an antisense oligonucleotide (ASO), a synthetic single-stranded molecule designed to bind a specific target RNA sequence using base-pairing. In RP11, the working hypothesis is that the healthy second copy of the PRPF31 gene is suppressed in affected cells, and the ASO is intended to relieve that suppression and allow the functional copy to produce more protein. VP-001 is delivered directly into the eye by intravitreal injection, a route that bypasses the systemic delivery limitations common to ASOs used in other disease areas.
- What the trial is measuring, and why it matters
- The lead Phase 1/2 trial (NCT06852963) is a repeat-dose, open-label, two-arm study comparing two dose levels of VP-001, with a primary completion date of March 2028 (per ClinicalTrials.gov NCT06852963). Completed earlier Phase 1 studies examined single ascending doses (SAD, NCT05902962) and multiple ascending doses (MAD, NCT06455826) to characterise safety and tolerability. The Phase 1/2 study is expected to generate both safety and efficacy data, with endpoints relevant to retinal function and disease progression, though the specific primary and secondary endpoints are listed below in the design section.
- Efficacy benchmarks in this setting
- There are no approved disease-modifying therapies for RP11 against which a direct efficacy benchmark can be drawn. In the broader retinitis pigmentosa space, voretigene neparvovec (Luxturna) is approved by the FDA for a distinct genetic subtype (RPE65 mutation-associated retinal dystrophy) and demonstrated improvements in a multi-luminance mobility test in a Phase 3 trial (Russell et al, Lancet 2017); this approval covers a different gene and patient population and is not directly comparable to RP11. Given that the VP-001 trials are early-stage (Phase 1 and Phase 1/2), any efficacy figures reported to date are not statistically comparable to results from randomised, adequately-powered trials in approved therapies.
- Commercial context
- No disease-modifying therapy is currently approved specifically for RP11. The European Medicines Agency (EMA) granted Orphan Drug Designation for VP-001 in RP11 (per ASX announcement, 26 April 2026), which confers certain regulatory and market exclusivity incentives in the European Union. VP-001 appears to be a lead clinical asset for PYC Therapeutics based on the volume of announced trial activity and investor communications. No licensing deal or partnership terms have been disclosed in the available announcements. Intravitreal ASO delivery is an established route, with fomivirsen (Vitravene) being an early approved example of an intravitreal ASO, though that product was withdrawn for commercial reasons unrelated to safety (per FDA records).